(Press-News.org) Prague, Czechia – 20 May 2023: People with strong legs are less likely to develop heart failure after a heart attack, according to research presented today at Heart Failure 2023, a scientific congress of the European Society of Cardiology (ESC).1
Myocardial infarction is the most common cause of heart failure,2 with around 6–9% of heart attack patients going on to develop the condition.3,4 Previous research has shown that having strong quadriceps is associated with a lower risk of death in patients with coronary artery disease.5
This study tested the hypothesis that leg strength is associated with a lower risk of developing heart failure after acute myocardial infarction. The study included 932 patients hospitalised in 2007 to 2020 with acute myocardial infarction who did not have heart failure prior to the admission and did not develop heart failure complications during their hospital stay. The median age was 66 years and 753 participants (81%) were men.
Maximal quadriceps strength was measured as an indicator of leg strength. Patients sat on a chair and contracted the quadriceps muscles as hard as possible for five seconds. A handheld dynamometer attached to the ankle recorded the maximum value in kg. The measurement was performed on each leg and the researchers used the average of both values. Strength was expressed relative to body weight, meaning that quadriceps strength in kg was divided by body weight in kg and multiplied by 100 for a % body weight value. Patients were classified as ‘high’ or ‘low’ strength according to whether their value was above or below the median for their sex.
The median value for women was 33% body weight and the median value for men was 52% body weight. A total of 451 patients had low quadriceps strength and 481 had high strength. During an average follow-up of 4.5 years, 67 patients (7.2%) developed heart failure. The incidence of heart failure was 10.2 per 1,000 person-years in patients with high quadriceps strength and 22.9 per 1,000 person-years in those with low strength.
The researchers analysed the association between quadriceps strength (low vs. high) and the risk of developing heart failure. The analysis was adjusted for factors known to be associated with the development of heart failure after myocardial infarction including age, sex, body mass index, prior myocardial infarction or angina pectoris, diabetes, atrial fibrillation, chronic obstructive pulmonary disease, peripheral arterial disease and kidney function. Compared with low quadriceps strength, a high strength level was associated with a 41% lower risk of developing heart failure (hazard ratio [HR]: 0.59; 95% confidence interval [CI] 0.35–1.00; p=0.048).
The investigators also analysed the association between quadriceps strength as a continuous variable and the risk of developing heart failure. Each 5% body weight increment in quadriceps strength was associated with an 11% lower likelihood of heart failure (HR 0.89; 95% CI 0.81–0.98; p=0.014).
Study author Mr. Kensuke Ueno, a physical therapist at the Kitasato University Graduate School of Medical Sciences, Sagamihara, Japan said: “Quadriceps strength is easy and simple to measure accurately in clinical practice. Our study indicates that quadriceps strength could help to identify patients at a higher risk of developing heart failure after myocardial infarction who could then receive more intense surveillance. The findings need to be replicated in other studies, but they do suggest that strength training involving the quadriceps muscles should be recommended for patients who have experienced a heart attack to prevent heart failure.”
ENDS
Authors: ESC Press Office
Tel: +33 (0)489 872 075
Email: press@escardio.org
Follow us on Twitter @ESCardioNews
Notes to editor
Funding: This work was partially supported by the Japan Society for the Promotion of Science (JSPS) KAKENHI Grant Number 21H03309.
Disclosures: The authors have no conflicts of interest to report.
References and notes
1The abstract ‘Leg strength and incidence of heart failure in patients with acute myocardial infarction’ will be presented during the session ‘Rehabilitation and Sports Cardiology - Cardiovascular Rehabilitation’ which takes place on 20 May at 16:00 CEST at Moderated ePosters 3.
2Jenča D, Melenovský V, Stehlik J, et al. Heart failure after myocardial infarction: incidence and predictors. ESC Heart Fail. 2021;8:222–237.
3Lewis EF, Moye LA, Rouleau JL, et al. Predictors of late development of heart failure in stable survivors of myocardial infarction: the CARE study. J Am Coll Cardiol. 2003;42:1446–1453.
4Spencer FA, Meyer TE, Gore JM, Goldberg RJ. Heterogeneity in the management and outcomes of patients with acute myocardial infarction complicated by heart failure. Circulation. 2002;105:2605–2610.
5Kamiya K, Masuda T, Tanaka S, et al. Quadriceps strength as a predictor of mortality in coronary artery disease. Am J Med. 2015;128:1212–1219.
About Heart Failure 2023 & World Congress on Acute Heart Failure
Heart Failure is the annual congress of the Heart Failure Association (HFA) of the European Society of Cardiology (ESC).
#HeartFailure2023
About the Heart Failure Association
The Heart Failure Association (HFA) is a branch of the European Society of Cardiology (ESC). Its aim is to improve quality of life and longevity, through better prevention, diagnosis and treatment of heart failure, including the establishment of networks for its management, education and research.
About the European Society of Cardiology
The European Society of Cardiology brings together health care professionals from more than 150 countries, working to advance cardiovascular medicine and help people lead longer, healthier lives.
Information for journalists about registration for Heart Failure 2023
Heart Failure 2023 takes place 20 to 23 May at the O2 universum in Prague, Czechia and online. Explore the scientific programme.
Free registration applies to accredited press.
Credentials: A valid press card or appropriate letter of assignment with proof of three recent published articles. Read the ESC media and embargo policy.
The ESC Press Office will verify the documents and confirm by email that your press accreditation is valid.
The ESC Press Office decision is final regarding all press registration requests. END
Heart attack patients with strong legs have better prognosis
2023-05-20
ELSE PRESS RELEASES FROM THIS DATE:
Remote monitoring reduces heart failure hospitalizations and improves quality of life
2023-05-20
Prague, Czechia – 20 May 2023: The first investigator-initiated study of remote pulmonary artery pressure monitoring has found that it improves quality of life and reduces heart failure hospitalisations in patients with chronic heart failure. The findings are presented today in a late breaking science session at Heart Failure 2023, a scientific congress of the European Society of Cardiology (ESC),1 and published in The Lancet.
Principal investigator Dr. Jasper Brugts of Erasmus University Medical Centre, ...
A Spanish team presents the first pharmacological treatment able to improve cardiac function in stiff-heart syndrome
2023-05-20
Transthyretin-related cardiac amyloidosis is a progressive disease characterized by the deposition of amyloid protein fibrils in the heart. Amyloid fibril deposition thickens and stiffens the heart walls, and the disease is also known as stiff-heart syndrome. The accumulation of amyloid fibrils causes heart failure, and patients suffer from fluid retention, fatigue, and arrhythmias. The disease can be caused by genetic mutations or related to aging. Prognosis is poor, and untreated patients survive for an average of just 3 years.
Now, the ...
George Dangas, MD, Ph.D., named President of Society for Cardiovascular Angiography & Interventions
2023-05-20
The Society for Cardiovascular Angiography & Interventions (SCAI) has named George Dangas, MD, PhD, Professor of Medicine (Cardiology), and Surgery, at the Icahn School of Medicine at Mount Sinai as its new President. He was appointed on Saturday, May 20, during the closing ceremonies at the SCAI 2023 Scientific Sessions in Phoenix. He is the first Mount Sinai cardiologist to hold this position and will serve as the 46th President of SCAI.
Dr. Dangas, also the Director of Cardiovascular Innovation at the Zena and Michael A. Wiener Cardiovascular Institute at Icahn Mount Sinai and Chief of Cardiology ...
Forging partnerships in the Americas: Naval leaders gather at SIANC S&T Conference
2023-05-20
ARLINGTON, Va.—For Dr. Brett Seidle — the deputy assistant secretary of the Navy for Research, Development, Test and Engineering — the breakneck speed of current scientific progress and technological proliferation can be challenging, especially when the impact of new technologies on civilian and military realities transcends national borders.
While giving the keynote address at the recent Specialized Inter-American Naval Conference on Science, Technology and Innovation (SIANC-ST&I) in Orlando, Florida, Seidle identified several scientific disciplines that have developed into ...
New study reveals possible future health impacts related to climate mitigation
2023-05-20
UNIVERSITY PARK, Pa. — Reduce fossil fuel use and air quality will improve, right? It might not be as straightforward as it appears, according to a Penn State-led research team. They explored almost 30,000 simulated future scenarios and found that some climate mitigation efforts could lead to harmful health impacts in certain geographic areas.
Their results were published today (May 18) in Nature Sustainability.
“In general, reducing fossil fuel use is good for climate mitigation and good for cleaning up the air, and the modeling studies have always found health benefits from climate mitigation,” said corresponding ...
Study finds cardiovascular risk score improves after one year of semaglutide use in patients with overweight and obesity
2023-05-20
New research presented at this year’s European Congress on Obesity in Dublin, Ireland shows that patients treated with the obesity drug semaglutide have a decreased cardiovascular risk score after one year of use. The study is by Dr Andres Acosta and Dr Wissam Ghusn, Precision Medicine for Obesity Program at the Mayo Clinic, Rochester, MN, USA and colleagues.
Obesity is a major risk factor for the development of abnormal blood fat levels, type-2 diabetes mellitus (T2DM), high blood pressure, and obstructive sleep apnoea. These comorbidities are associated with an increased risk of cardiovascular disease (CVD) that represents ...
Semaglutide shown to be effective for weight loss in multicentre, one-year real-world study
2023-05-20
New research presented at this year’s European Congress on Obesity (ECO2023, Dublin, 17-20 May) shows that the obesity drug semaglutide is effective for weight loss in a multicentre, 1-year-long real-world study. The study is by Dr Andres Acosta and Dr Wissam Ghusn, Precision Medicine for Obesity Program at the Mayo Clinic, Rochester, MN, USA and colleagues.
Semaglutide, a glucagon-like peptide-1 (GLP-1) receptor agonist, is the most recently FDA-approved anti-obesity medication. It has shown significant weight loss outcomes in multiple long-term randomised clinical trials and short-term real-world studies. However, little is known about ...
Consequences of uncontrolled hunger in teenagers living with obesity examined in international study
2023-05-20
Teenagers living with obesity who say hunger is preventing them from losing weight (hunger-barrier ALwO) perceive their weight more negatively and worry about it more than youngsters who don’t see hunger as an obstacle, new research being presented at the European Congress on Obesity (ECO) in Dublin, Ireland (17-20 May) shows.
The international study also found that hunger-barrier ALwO are more likely to be female and more likely to say their weight makes them unhappy and leads to them being bullied. They are also more likely to be actively trying to lose weight.
Dr Bassam Bin-Abbas, of the Department of Paediatrics, King Faisal Specialist Hospital and Research Center, Riyadh, ...
Stress hormone measured in hair predicts who is likely to suffer from cardiovascular diseases
2023-05-20
New research being presented at this year’s European Congress on Obesity (ECO) in Dublin, Ireland (17-20 May) suggests that glucocorticoid levels (a class of steroid hormones secreted as a response to stress) present in the hair of individuals may indicate which of them are more likely to suffer from cardiovascular diseases (CVD) in the future.
“There is a tremendous amount of evidence that chronic stress is a serious factor in determining overall health. Now our findings indicate that people with higher long-term hair glucocorticoid ...
New high risk, high reward studies will tackle key unanswered questions about our planet
2023-05-20
NERC has invested £25 million in a host of high risk, high reward research projects to tackle critical environment challenges.
The 44 projects cover the full spectrum of environmental science including geology, atmospheric science, biodiversity and ecology.
The research will, for example:
improve our understanding of volcanic activity such as eruptions a lava flows
age the Earth’s solid inner core
investigate historic mass extinction events
predict future changes to carbon ...